OnKure Announces the Appointment of Rogan Nunn, J.D., as General Counsel and Secretary
June 19 2024 - 5:42PM
OnKure, Inc. today announced the appointment of Rogan Nunn as
General Counsel and Secretary. Mr. Nunn will be a member of
OnKure’s Executive Team, reporting to Nicholas Saccomano, President
and Chief Executive Officer, and will oversee all aspects of the
Company’s legal and compliance functions.
"We are delighted to welcome Rogan to OnKure as our new General
Counsel and Secretary," said Dr. Saccomano. "Rogan's extensive
legal expertise and strategic insight will be invaluable as we
continue to advance our programs."
“I’m thrilled to be joining OnKure at such a pivotal and
exciting time in its evolution,” said Mr. Nunn. “We have an
extraordinarily talented and dedicated team here. Together, I
believe we have a real opportunity to advance the state of
treatment and make a meaningful difference in the lives of
patients.”
Prior to joining OnKure, Mr. Nunn served as General Counsel,
America at ADC Therapeutics, where he oversaw global legal
operations and executed transactions across the U.S., Europe and
Asia. Before ADC, Mr. Nunn served as EVP, General Counsel and
Secretary of Array Biopharma until Array’s sale to Pfizer. Prior to
moving in-house at Array Biopharma, Mr. Nunn was a corporate and
M&A specialist at Skadden, Arps, Slate, Meagher & Flom,
where he counseled boards and executive teams of both public and
private companies in a diverse array of corporate matters, with a
particular focus on life sciences and biotechnology.
Mr. Nunn holds a BS in Finance and International Business from
Georgetown University and a Juris Doctor from the University of
Virginia School of Law.
About OnKure
OnKure, Inc. is a clinical-stage biopharmaceutical company
focused on the discovery and development of best-in-class precision
medicines that target biologically validated drivers of cancers
that are underserved by available therapies. Using structure-based
drug design portfolio, OnKure is building a pipeline of
tumor-agnostic candidates that are designed to achieve optimal
efficacy and tolerability. OnKure is currently developing OKI-219,
a selective PI3KαH1047R inhibitor, as its lead program. OnKure
aims to become a leader in targeting oncogenic PI3Kα and has
multiple programs designed to enable best-in-class targeting of
this key oncogene.
For more information about OnKure, visit us at www.onkure.com
and follow us on LinkedIn.
Contacts:
Investors:
IR@onkure.com